Tumor-associated ganglioside antigen is a class of tumor-associated glycolipid molecules. This class of glycolipid molecules is commonly expressed on the surface of tumor cells and is less or not expressed in healthy tissues. To cater to the demands of related research, CD BioGlyco has allocated substantial resources towards research and development. We have a professional team that utilizes state-of-the-art technology and equipment to ensure that the tumor-associated ganglioside antigen we produce is of high purity and bioactivity through fine preparation processes and strict quality control. We offer a wide range of tumor-associated ganglioside antigen production services, encompassing but not limited to the following.
Ganglioside antigen has been extensively studied in breast cancer and its overexpression is associated with breast cancer cell growth and metastasis. For this reason, we also offer our clients the development of subsequent anti-tumor vaccines based on the produced tumor-associated ganglioside antigen.
Fig.1 Structure of ganglioside GD2. (Machy, et al., 2023)
Antigens are a key component in the preparation and modification of antibodies during antibody drug development. Researchers typically use antigens to immunize animals by stimulating the immune system to produce specific antibodies. These antibodies can bind to the antigen and produce the desired effect.
As biotechnology continues to evolve, new methods are being developed to produce tumor-associated ganglioside antigens. For example, large-scale and precise production can be achieved using cell engineering techniques and gene editing technologies.
CD BioGlyco has equipped an advanced Glyco™ Vaccine Development Platform and experienced researchers to provide clients with a specialized and comprehensive tumor-associated ganglioside antigen production service. If you need more information about our services, please contact us for the details.
Reference
